Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Oteracil

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Oteracil: Patents, clinical trial progress, indications

Oteracil is an investigational drug.

There have been 64 clinical trials for Oteracil. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Head and Neck Neoplasms. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Quintiles, Inc.

There are eighty-six US patents protecting this investigational drug and eight hundred and eighteen international patents.

Recent Clinical Trials for Oteracil
SOX-based CRT for Esophageal Cancer.Zhejiang Provincial People’s HospitalPhase 1/Phase 2
S-1 for 9 Months Versus 1 Year for Gastric Cancer Staged II(SMAC)Fudan UniversityPhase 2
Tegio Consolidation Therapy for NPC Patients With High Risk of MetastasisZhejiang Cancer HospitalPhase 2

See all Oteracil clinical trials

Clinical Trial Summary for Oteracil

Top disease conditions for Oteracil
Top clinical trial sponsors for Oteracil

See all Oteracil clinical trials

US Patents for Oteracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Oteracil   Start Trial Chromane herbicides E. I. Du Pont de Nemours and Company (Wilmington, DE)   Start Trial
Oteracil   Start Trial Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)   Start Trial
Oteracil   Start Trial Salts of optically active 4-hydroxy-8(3-lower alkoxy-4-phenylsulfinylphenyl)pyrazolo(1,5-A)-1,3,5- triazines and a process for production thereof Otsuka Pharmaceutical Factory, Inc. (Tokushima, JP)   Start Trial
Oteracil   Start Trial Prodrugs for selective drug delivery   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.